Argentina Lab Closures: Four Labs Lose Sanitary Authorization

Argentine Regulator Suspends four Pharmaceutical Companies

Argentina’s National Administration of Medicines, Food and Medical Technology (Anmat) revoked the⁣ operating licenses of four pharmaceutical⁤ companies for‍ operating without a qualified technical director, according to an official notice published⁢ in the Official Bulletin on January 15, 2026.

Details of the Suspension

The Anmat initiated these actions following a systematic control‍ process that revealed deficiencies in the companies’ operations. The agency’s Registry ‍of Establishment Registration identified the lack of a technical director⁤ as a critical violation of regulatory standards. These ⁢suspensions formalize measures ⁤initially ‍announced in november 2025.

While the names of the four companies were ⁤not immediately released in the initial report, anmat indicated further ⁢details would be available through its official channels. The agency’s decision underscores its‍ commitment to⁢ ensuring the safety and efficacy of ⁣pharmaceutical products available to the public.

Anmat’s Regulatory Authority

Anmat is the Argentine government agency responsible for regulating and controlling medicines, food, and medical technology.It ⁣operates under the Ministry of Health and is tasked with protecting public health by ensuring that products meet established quality, safety, and efficacy standards. The agency conducts inspections, audits, ⁤and laboratory analyses to verify compliance with regulations.

In 2024,Anmat issued Resolution 1488/2024,outlining the requirements for technical directors in pharmaceutical companies,emphasizing their role in ⁤overseeing quality control and ensuring adherence to ⁤good manufacturing practices. Resolution 1488/2024